Wyeth

Pfizer Corporation

Kodiak Sciences Inc.

Other

Laura Lin

William Stuart Somers

Mark L Stahl

Lidia Mosyak

Kevin Delos Parris

Lori J Fitz

Justin Cohen

James Bradley Aggen

Jose William Saldanha

Geertruida Machteld Veldman

Lioudmila Tchistiakova

Samuel Goldman

Debra D Pittman

Debra D Donaldson

Stephen A Charles

James Reasoner Apgar

Wayne To

Xiang-Yang Tan

Kimberly Ann Marquette

Angela Widom

Eric Feyfant

Tetsuya Ishino

Marion T Kasaian

Amy Szepui Tam

Tania Shane

Amy Sze Pui Tam

Nancy L Wood

Javier Fernando Chaparro Riggers

Didier G Benoit

Yik Andy Yeung

Daniel Victor Perlroth

D Victor Perlroth

Robert L Powers

Stephane Olland

Guang-Yi Xu

Chuenlei Parng

Divya Chaudhary

Zhang Bao Xu

Karl Malakian

Scott Wolfrom

Julie Lee

Rita Greco

Sheryl Rubio Bowley

Joanne Elizabeth-Ayriss Elwell

Jatin Narula

Didler Benoit

Swapnil Rakhe

Reid Martin Renny Feldman

Chihyi Vincent Yu

Ling Hon Matthew Chu

Ivana Djuretic

The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to E-selectin. The invention includes uses, and associated methods of using the antibodies, and antigen-binding fragments thereof.

Anti-E-selectin antibodies, compositions and methods of use

The invention provides a dual VEGF/PDGF antagonist comprising a VEGF antagonist linked to a PDGF antagonist. The VEGF antagonist is an antibody to a VEGF or VEGFR or is a VEGFR extracellular trap segment (i.e., a segment from the extracellular region of one or more VEGFR receptors that inhibits binding of at least one VEGFR to at least one VEGF). The PDGF antagonist is an antibody to a PDGF or PDGFR or is a PDGFR extracellular trap segment (i.e., segment from the extracellular region of one or more PDGFRs, which inhibits binding of at least one PDGFR and at least one PDGF). The dual antagonist is preferably conjugated to a half-life extending moiety, such as a HEMA-PC polymer. The dual antagonist is particularly useful for treating wet aged related macular degeneration.

Dual PDGF/VEGF antagonists

The present invention relates to human interleukin 15 (IL-15) variants that have therapeutic and diagnostic use, and methods for making thereof. The present invention also provides fusion proteins comprising a human IL-15 variant. Also provided are methods of stimulating or suppressing immune responses in a mammal, and methods of treating a disorder (e.g., cancer) using the IL-15 variants or the fusion protein of such IL-15 variants.

IL-15 variants and uses thereof

The present disclosure provides muteins of FVIII to which a biocompatible polymer may be attached to increase the circulatory half-life of the muteins, as well as conjugates of such muteins and biocompatible polymers.

Muteins of clotting factor VIII

This application relates to antibodies, e.g., humanized antibodies, and antigen-binding fragments thereof, that bind to interleukin-13 (IL-13), in particular, human IL-13, and their uses in regulating immune responses mediated by IL-13. The antibodies disclosed herein are useful in diagnosing, preventing, and/or treating a subject, e.g., a human patient, one or more IL-13-associated disorders, e.g., respiratory disorders (e.g., asthma); atopic disorders (e.g., allergic rhinitis); inflammatory and/or autoimmune conditions of the skin (e.g., atopic dermatitis), and gastrointestinal organs (e.g., inflammatory bowel diseases (IBD)), as well as fibrotic and cancerous disorders.

Antibodies against human interleukin-13 and uses therefor

Antibodies against human interleukin-13 and pharmaceutical compositions thereof

A three-dimensional structure of human protein kinase C theta (PKC&#x3b8;) can be used in methods of designing an agent that interacts with PKC&#x3b8;. The agent can be an inhibitor of PKC&#x3b8; activity.

Structure of protein kinase C theta

This invention is directed to the crystal structure of Acyl Carrier Protein Synthase (ACPS) complexed with Acyl Carrier Protein (ACP), the solution structure ofACP, and to the use of these structures in rational drug design methods to identify agents that may interact with active sites of ACPS and ACP, and to the testing of these agents to identify agents that may represent novel antibiotics.

Crystals of an acyl carrier protein synthase/acyl carrier protein complex

This invention is directed to the crystal structure of Acyl Carrier Protein Synthase (ACPS) complexed with Acyl Carrier Protein (ACP), the solution structure of ACP, and to the use of these structures in rational drug design methods to identify agents that may interact with active sites of ACPS and ACP, and to the testing of these agents to identify agents that may represent novel antibiotics.

Methods for identifying agents that interact with an active site of acyl carrier protein synthase-acyl carrier protein complex

Growing community of inventors

Weston, MA, United States of America

Laura Lin